At what prices did Mark Eisner’s recent Vir Biotechnology (VIR) share sales occur?

Mark Eisner sold Vir Biotechnology common stock at average prices of $9.5326 and $9.82 per share. The first sale covered 1,616 shares at $9.5326, and the second covered 1,889 shares at $9.82, as disclosed in the Form 4 filing.

Vir Biotechnology (VIR) CMO reports 3,505-share Rule 10b5-1 stock sale

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vir Biotechnology, Inc. executive vice president and chief medical officer Mark Eisner reported two open-market sales of common stock under a pre-set Rule 10b5-1 trading plan. On February 24, 2026, he sold 1,616 shares at an average price of $9.5326 per share. On February 25, 2026, he sold another 1,889 shares at an average price of $9.82 per share. A footnote states the February 25 sale was an automatic, mandatory sale to cover tax withholding from vested restricted stock units rather than a discretionary trade. After these transactions, Eisner directly owned 154,024 shares of Vir Biotechnology common stock.

Insider Trade Summary

Net Seller: 3,505 shares ($33,955)

Net Sell 2 txns

Insider Eisner Mark

Role EVP and Chief Medical Officer

Sold 3,505 shs ($34K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,889	$9.82	$19K
Sale	Common Stock	1,616	$9.5326	$15K

Holdings After Transaction: Common Stock — 154,024 shares (Direct)

Footnotes (1)

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

Form 4 Insider Transactions: What Each Field Means →

02/26/2026 - 04:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eisner Mark

(Last)

(First)

(Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO

94158

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/24/2026		S⁽¹⁾		1,616	D	$9.5326	155,913	D
Common Stock	02/25/2026		S⁽²⁾		1,889	D	$9.82	154,024	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Vir Biotechnology (VIR) report for Mark Eisner?

Vir Biotechnology EVP and chief medical officer Mark Eisner reported selling a total of 3,505 common shares in two open-market transactions. These trades occurred on February 24 and 25, 2026, under a pre-arranged Rule 10b5-1 trading plan, according to the Form 4.

How many Vir Biotechnology (VIR) shares does Mark Eisner hold after these sales?

After the reported Form 4 transactions, Mark Eisner directly owns 154,024 shares of Vir Biotechnology common stock. This figure reflects his holdings following the February 25, 2026 sale, which reduced his position by 1,889 shares that day.

Were Mark Eisner’s Vir Biotechnology (VIR) stock sales discretionary trades?

The Form 4 footnotes state the February 25, 2026 sale was an automatic, mandatory transaction under Rule 10b5-1 to satisfy tax withholding on vested restricted stock units. It notes this sale did not represent a discretionary trade by Eisner.

What is the Rule 10b5-1 trading plan mentioned for Vir Biotechnology (VIR) insider trades?

The filing explains that the reported sales were made under a Rule 10b5-1 trading plan. It notes this plan was adopted by Mark Eisner on May 19, 2025, allowing pre-scheduled trades executed automatically according to pre-set instructions.